The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

Back to all Disease Areas
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Tumor-agnostic
An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
Funda Meric-Bernstam
View presentation
Poster
Valemetostat
ASCPT 2025 | May 28-31, 2025
Tumor-agnostic
Effect of valemetostat on the pharmacokinetics of midazolam and digoxin (CYP3A and P-gp substrates): A phase 1 drug–drug interaction study in patients with refractory or relapsed non-hodgkin lymphoma
Masaya Tachibana
View presentation
Oral
Other/Multi
JSMO 2025 | March 6-8, 2025
Tumor-agnostic
Expression of tumor-associated mucin 1 in bladder and upper urinary tract cancers
Chihiro Nakayama-Kondoh
View presentation
Poster
I-DXd
ASCO 2025 | May 30-June 3,2025
Tumor-agnostic
IDeate-PanTumor02: A phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with recurrent or metastatic solid tumors
Takahiro Kogawa
View presentation
Poster
Other/Multi
ACoP16 | October 18-21, 2025
Tumor-agnostic
QSP I-O & ADCs: Integration of an antibody-drug conjugates mechanistic model into an immuno‐oncology quantitative systems pharmacology platform
Yafei Wang
View presentation
Poster
R-DXd
ASCO 2025 | May 30-June 3,2025
Tumor-agnostic
REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic solid tumors
Laurence Albiges
View presentation
Poster
Dato-DXd
ASCPT 2025 | May 28-31, 2025
Tumor-agnostic
Reverse-translational findings for datopotamab deruxtecan (Dato-DXd) human efficacious dose prediction based on mechanistic PK/tumor growth inhibition analysis for patient-derived and cancer cell line-derived xenograft mice
Tsuyoshi Karibe
View presentation
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Tumor-agnostic
Trastuzumab deruxtecan for pretreated patients with HER2-expressing solid tumors: DESTINY-PanTumor02 part 1 final analysis
Vicky Makker
View presentation
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Tumor-agnostic
Trastuzumab deruxtecan in pretreated patients with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 part 1
Jung-Yun Lee
View presentation
Connect with an MSL
Linkedin Icon Twitter Icon

©2024 Daiichi Sankyo, Inc. All Rights Reserved. The information provided in this site is intended for U.S. healthcare professionals only. The compounds discussed herein may have different product labeling in different countries.

MED-US-GOA-00007 06/24

TERMS & CONDITIONS PRIVACY NOTICE CONTACT US

MED-US-GOA-00007 06/24